Prelude Capital Management, LLC Fennec Pharmaceuticals Inc. Transaction History
Prelude Capital Management, LLC
- $1.39 Billion
- Q2 2024
Shares
5 transactions
Others Institutions Holding FENC
# of Institutions
67Shares Held
14.3MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$17.4 Million0.73% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$10.3 Million30.37% of portfolio
-
Dg Capital Management, LLC New York, NY1.63MShares$6.96 Million3.85% of portfolio
-
Solas Capital Management, LLC Darien, CT1.34MShares$5.71 Million4.92% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$5.06 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $111M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...